Introduction
As a metabolic chronic disease, diabetes has severely affected people's health. Evidence
suggested that α-glucosidase inhibitors, such as acarbose, miglitol as well as voglibose,
can lower the glucose levels in plasma by delaying the absorbance of carbohydrates,
and are used clinically to treat diabetes; however, they also bring adverse reactions
such as abdominal pain, flatulence, and diarrhea.[1 ] Thus, the discovery of natural, side-effect-free, and effective α-glucosidase inhibitors
from widely sourced medicinal plants are of important value for the treatment of diabetes.
Hyperglycemia is the major symptom of diabetes. It is well known that Morus plants are famous for their antihyperglycemia effects, and has received much attention
in diabetes treatment. The isolated alkaloids from Morus plants, such as 1-deoxynojirimycin, and phenolic components have demonstrated antidiabetes
activity by exhibiting potent α-glucosidase inhibitory activity.[2 ]
[3 ] Thus, Morus plants may be a natural source for drug discovery for diabetes therapy.
Morus nigra Linn., as a deciduous shrub or tree, belongs to the Morus genus (Moraceae). The plant of M. nigra was introduced from western Iran in the 16th century and mainly distributed in southern
Xinjiang province, China.[4 ] Our previous program for screening antidiabetic bioactive substances has afforded
a series of active compounds from M. nigra .[5 ]
[6 ]
[7 ] As a continuous study, this research provided 12 compounds (1 –12 ), including a new sanggenon-type flavanone (1 ) and a new natural product (10 ). All of them were evaluated for their α-glucosidase inhibition activity, and six
compounds showed significant inhibitory activity with IC50 values ranging from 1.24 to 19.00 µmol/L. Our article provided novel potential compounds
for the treatment of diabetes in the future.
Materials and Methods
General Methods
Ultraviolet (UV) spectra were collected using a UV-2500 PC instrument (Shimadzu Corporation,
Japan). Mass spectrometry was determined on a Waters Xevo G2-XS-Q-TOF. Nuclear magnetic
resonance (NMR) spectra were recorded on a Bruker AV III instrument. Electronic circular
dichroism spectra were obtained using a JASCO-810 spectropolarimeter. Silica gel (200–300
mesh, Qingdao Haiyang Chemical Co, Ltd.), Sephadex LH-20 (GE Healthcare, Sweden),
and RP-C18 (YMC Co., Ltd., Japan) were used for column chromatography (CC). Thin layer
chromatography was performed on silica gel HF254 plates using 10% H2 SO4 in ethanol (v/v) spray reagents followed by heating. Semipreparative high-performance
liquid chromatography (HPLC) was carried out on a LC3050N HPLC using a C18 column
(10 × 250 mm, 5 μm, Waters Corporation, United States) and characteristic UV absorption
at 210 nm. Reagents were of analytical reagent grade (Sinopharm Chemical Reagent Co.,
Ltd., Shanghai, China) except for acetonitrile and methanol which were of chromatographic
grade.
Plant Materials
The stems of M. nigra L. (Moraceae) were collected from Hetian town, in the Xinjiang province of China
in September 2016. The plant was identified by Prof. Tong Wu, who comes from China
State Institute of Pharmaceutical Industry, China. A voucher specimen (No. 201609001)
was deposited in our department.
Extraction and Isolation
The dried and powered stems of M. nigra (15 kg) were extracted twice with 90% aqueous EtOH under hot reflux (1.5 hours each
time). The concentrated extract was suspended in water and partitioned successively
with petroleum ether (PE), dichloromethane (DCM), ethyl acetate (EtOAc), and n -butanol. The crude extracts of DCM portion (120 g) and EtOAc portion (80 g) were
mixed and then subjected to silica gel CC, eluted with CH2 Cl2 –CH3 OH (80:1 → 1:1) to obtain six fractions (Fr.A–Fr.F). Fr.A (42.5 g) was purified by
silica gel CC (PE–acetone, 15:1 → 1:1) to obtain 18 subfractions (Fr.A-1–Fr.A-18).
Fr.A-8 (13.3 g) was decolored with HP-20 macroporous-absorbing resin eluted with EtOH
to get a fraction (Fr.A-8-1). Fr.A-8-1 was further separated by CC successively over
Sephadex LH-20 (CH2 Cl2 –CH3 OH, 1:1) and RP-C18 (CH3 OH–H2 O, 50:50 → 100:0) to obtain five fractions (Fr.A-8-1-a–Fr.A-8-1-e). Fr.A-8-1-a (56.0 mg)
was purified by semipreparative HPLC (CH3 CN–H2 O, 18:82) to yield compound 9 (1.7 mg) and compound 11 (3.5 mg). Fr.A-8-1-b (14.7 mg) was separated by semipreparative HPLC eluted with
a gradient of CH3 CN–H2 O (28:72 → 35:65) to afford compound 10 (3.0 mg). Fr.A-9 (1.3 g) was chromatographed over Sephadex LH-20 (CH2 Cl2 –CH3 OH, 1:1), followed by CC on RP-C18 (CH3 OH–H2 O, 60:40 → 90:10), to give two fractions (Fr.A-9-1–Fr.A-9-2). Fr.A-9-2 (30.0 mg) was
further subjected to semipreparative HPLC (CH3 CN–H2 O, 25:75) to yield compound 12 (3.0 mg). Fr.A-11 (0.8 g) was chromatographed on Sephadex LH-20 (CH2 Cl2 –CH3 OH, 1:1) to give a fraction (Fr.A-11-3). Fr.A-11-3 (125.7 mg) was separated by silica
gel CC (CH2 Cl2 –CH3 OH, 100:1 → 10:1) to obtain two fractions (Fr.A-11-3-1–Fr.A-11-3-2). Fr.A-11-3-1 (18.5 mg)
and Fr.A-11-3-2 (35.4 mg) were further purified by semipreparative HPLC to yield compound
6 (2.0 mg) and compound 7 (11.4 mg), respectively. Fr.A-13 (3.4 g) was chromatographed over Sephadex LH-20
(CH2 Cl2 –CH3 OH, 1:1) to produce a fraction (Fr.A-13-1), which was subjected to CC on RP-C18 (CH3 OH–H2 O, 50% → 100%) to produce three parts (Fr.A-13-1-1–Fr.A-13-1-3). Fr.A-13-1-1 (174.5 mg)
and Fr.A-13-1-2 (82.7 mg) were further purified by semipreparative HPLC (CH3 CN–H2 O, 70:30) to afford compounds 1 (5.6 mg) and 4 (3.6 mg), respectively. By a similar procedure to Fr.A-13, Fr.A-14 (1.4 g) was subjected
successively to CC on Sephadex LH-20 (CH2 Cl2 –CH3 OH, 1:1) and RP-C18 (CH3 OH–H2 O, 50:50 → 90:10), followed by semipreparative HPLC, to yield compound 5 (26.6 mg). Fr.B (6.6 g) was initially isolated by Sephadex LH-20 (CH2 Cl2 –CH3 OH, 1:1), followed by RP-C18 eluted with CH3 CN–H2 O (20:80 → 70:30) to yield six fractions (Fr.B-1–Fr.B-6). Fr.B-2 (107.3 mg) was chromatographed
on silica gel CC (CH2 Cl2 –CH3 OH, 60:1, 50:1, 40:1, 20:1, 10:1) to give one fraction (Fr.B-2-1), which afforded
compound 8 (1.0 mg) by semipreparative HPLC (CH3 CN–H2 O, 48:52). Fr.D (15.0 g) was initially divided into three fractions (Fr.D-1–Fr.D-3)
by CC on silica gel (PE–acetone, 5:1, 3:1, 2:1, 1:1). Fr.D-2 (5.0 g) was separated
by Sephadex LH-20 (CH2 Cl2 –CH3 OH, 1:1) to give four subfractions (Fr.D-2-1–Fr.D-2-4). Fr.D-2-2 (1.0 g) was isolated
into three portions (Fr.D-2-2-1–Fr.D-2-2-3) by CC on RP-C18 (CH3 OH–H2 O, 10:90 → 90:10). Fr.D-2-2-1 (47.7 mg) was further purified by semipreparative HPLC
(CH3 CN–H2 O, 23:77) to yield compound 2 (3.3 mg). Fr.D-3 (4.1 g) was subjected to CC on Sephadex LH-20 twice, eluted with
CH2 Cl2 –CH3 OH (1:1) to get one portion (Fr.D-3-2), which was further separated by CC on RP-C18
(CH3 OH–H2 O, 10:90 → 90:10) to afford four fractions (Fr.D-3-2-a–Fr.D-3-2-d). Fr.D-3-2-d (10.2 mg)
was purified by semipreparative HPLC to obtain compound 3 (2.0 mg).
α-Glucosidase Inhibition Assay
The α-glucosidase inhibitory activity was assessed with a spectrophotometric method[8 ] using acarbose as the positive control. Sample solution with six different concentrations
was preincubated with α-glucosidase (0.2 U/mL, Sigma Chemical Co. St. Louis, Missouri,
United States) in 96-well plates at 37°C for 10 minutes. Then the substrate 4-nitrophenyl-α-D-glucosidase
(PNPG, 100 µL, 2 mmol/L, Sigma Chemical Co., United States) was added to each well.
After incubation at 37°C for 20 minutes, the reaction was terminated with Na2 CO3 solution (50 μL, 1.06 g/50 mL). The absorbance of the system was measured at 405 nm
using a microplate reader. The IC50 was performed in triplicate and calculated with Graphpad Prism 7.0.
Results and Discussion
Structure Identification
Compound 1 was obtained as yellow powder. The molecular formula was established as C25 H26 O8 according to the [M − H]− ion peak at m /z 453.1555 (calcd. for C25 H25 O8 , 453.1549) in its HRESIMS (high-resolution electrospray ionization mass spectrometry)
spectrum. UV absorption maxima of compound 1 were recorded at 235 (sh), 285 (sh), and 310 nm, indicating the presence of a sanggenon-type
flavanone framework (3-hydroxy-2-prenylflavanones with a furan moiety between the
B and C rings) in this compound.[9 ] Besides, IR spectrum of compound 1 showed the existence of OH (3,395 cm−1 ), C = O (1,657 cm−1 ), and benzene ring (1,608 and 1,463 cm−1 ). Furthermore, the 1 H NMR spectrum of compound 1 ([Table 1 ]) showed (1) the signals of a hydrogen-bonded hydroxy group at δ
H 11.77 (1H, br s, OH-5); (2) an aromatic ABX spin system at δ
H 7.36 (1H, d, J = 8.4 Hz, H-6′ ), 6.52 (1H, dd, J = 8.4, 2.0 Hz, H-5′), and 6.39 (1H, d, J = 2.0 Hz, H-3′); (3) an aromatic proton at δ
H 5.80 (1H, s, H-6); and (4) a characteristic isoprenyl of sanggenon-type flavanone
at δ
H 5.24 (1H, br t, J = 7.6 Hz, H-10), 3.13 (1H, br dd, J = 14.8, 9.2 Hz, H-9a), 2.82 (1H, br dd, J = 14.8, 6.0 Hz, H-9b), 1.61 (3H, br s, H-13), and 1.51 (3H, br s, H-12).[7 ] In addition, signals of another cyclized isoprenyl group were observed at δ
H 4.77 (1H, br t, J = 8.4 Hz, H-15), 3.04 (2H, br d, J = 8.4 Hz, H-14), 1.23 (3H, s, H-17), and 1.22 (3H, s, H-18). A total of 25 carbon
signals appeared in the 13 C-NMR spectrum ([Table 1 ]), including 20 carbon signals from the sanggenon skeleton and 5 carbon signals from
the substituent. The key HMBC correlations of H2 -9 to C-3 and C-1′ assigned the isoprenyl group at C-2, confirming the sanggenon skeleton
of 1 . The HMBC correlations from H2 -14 to C-8a and C-16, and from H-15 to C-7, C-17, and C-18 indicated that the cyclized
isoprenyl group was fused at C-7 and C-8. Thus, its planar structure was established
as shown in [Fig. 1 ]. Furthermore, the absolute configurations of C-2 and C-3 in 1 were assigned as 2R and 3S respectively, according to the positive Cotton effects at 219, 251, 296, and 317 nm,
and negative Cotton effects at 239 and 276 nm in its circular dichroism (CD) spectrum[10 ] (see [Supplementary Figs. S1 ], [S2 ], [S3 ], [S4 ], [S5 ], [S6 ] [online only]). The absolute configuration of C-15 remained to be determined. Therefore,
compound 1 was elucidated as (6aS ,11bR )-6a,11b-dihydro-5,6a,9-trihydroxy-2-(1-hydroxy-1-methylethyl)-11b-(3-m ethyl-2-buten-1-yl)-1H ,2H ,6H -benzofuro[3,2-b]pyrano[2,3-e]-[1]benzofuro-6-one, and was named nigragenon F.
Fig. 1 Structures of compounds 1-12 isolated from M. nigra .
Table 1
1 H NMR (400 MHz) and 13 C NMR (100 MHz) data of 1 (in acetone-d
6 )
Position
δ
H (J in Hz)
δ
C
2
92.2
3
7.07 br s (OH)
102.5
4
188.4
4a
100.8
5
11.77 s (OH)
164.4
6
5.80 s
90.7
7
171.6
8
106.9
8a
159.5
9a
9b
3.13 dd (14.8, 9.2)
2.82 dd (14.8, 6.0)
32.1
10
5.24 br t (7.6)
119.0
11
136.6
12
1.51 s
25.9
13
1.61 s
18.1
14
3.04 d (8.4)
26.5
15
4.77 br t (8.4)
93.2
16
71.5
17
1.23 s
25.9
18
1.22 s
25.2
1′
121.3
2′
161.3
3′
6.39 d (2.0)
99.5
4′
8.72 br s (OH)
161.3
5′
6.52 dd (8.4, 2.0)
109.8
6′
7.36 d (8.4)
125.8
The structures of the remaining 11 compounds ([Fig. 1 ]) were elucidated as trans -resveratrol (2 ),[11 ] (E )-4-isopentenyl-3,5,2′,4′-tetrahydroxystilbene (3 ),[12 ] notabilisin E (4 ),[13 ] notabilisin A (5 ),[11 ] morusin (6 ),[14 ] petalopurpurenol (7 ),[15 ] 8-geranyl-5,7-dihydroxycoumarin (8 ),[16 ] 2,4-dihydroxybenzaldehyde (9 ),[17 ] 4-ethoxy-2,6-dihydroxybenzoic acid (10 ),[18 ] 3-hydroxy-4-methoxybenzaldehyde (11 ),[19 ] and 4-hydroxybenzaldehyde (12 )[20 ] by comparing their 1 H and 13 C NMR spectral data with those reported in the literature. Compound 10 was a new natural product, and 3 , 4 , 7 , and 8 were reported from the Morus g enus for the first time.
Compound 1 , nigragenon F, yellow powder; [α]25
D +66.9 (c 0.23, MeOH); UV λmax (MeOH) (log ε) 210 (3.03), 235 (sh) (1.32), 285 (sh) (3.09), 310 (4.94) nm. CD (MeOH)
λmax (Δε ) 219 (+2.31), 239 (−0.03), 251 (+0.57), 276 (−0.38), 296 (+0.72), 317 (+0.75) nm;
IR (KBr) νmax 3395, 2925, 1657, 1622, 1608, 1463, 1378, 1149 cm−1 ; 1 H and 13 C NMR data, see [Table 1 ]. Negative ion HRESIMS m /z : 453.1555 [M − H]− (calcd. for C25 H25 O8 , 453.1549).
Compound 10 , 4-ethoxy-2,6-dihydroxybenzoic acid, yellow-brown powder; MS (ESI) m /z : 197.04 [M − H]− , molecular formula: C9 H10 O5 ; 1 H-NMR (400 MHz, CD3 COCD3 ); δ
H 10.01 (2H, br s, OH-2/6), 5.93 (2H, s, H-3/5), 4.56 (2H, q, J = 7.2, 7.2 Hz, H-7), 1.44 (3H, t, J = 7.2 Hz, H-8); 13 C-NMR (100 MHz, CD3 COCD3 ); δ
C 169.9 (C-9), 164.8 (C-4), 163.0 (C-2/6), 95.5 (C-3/5), 93.3 (C-1), 62.1 (C-7), 13.7
(C-8).
α-Glucosidase Activity Screening
Compounds 1–12 were evaluated for their α-glucosidase inhibitory activity. All of them were initially
tested for their inhibitory rates at the concentration of 100 μmol/L. Preliminary
result showed that compounds 3 –8 exhibited obvious inhibitory effect with inhibition rates of more than 90%, while
the rest of the compounds with inhibition rates of below 50%. Then, IC50 values of 3 –8 were further determined. They showed potent inhibitory activities with IC50 values ranging from 1.24 to 19.00 µmol/L ([Table 2 ]). Of these, compound 5 showed the highest α-glucosidase inhibitory effect with IC50 value of 1.24 µmol/L, approximately 800 times stronger than the positive control
drug acarbose.
Table 2
The α-glucosidase inhibitory activities
Compounds
IC50 (µmol/L)[a ]
1
–
2
–
3
19.00 (17.49– 20.45)
4
1.72 (1.43– 2.09)
5
1.24 (1.19– 1.27)
6
4.72 (4.01– 5.91)
7
4.38 (2.35– 5.80)
8
12.01 (11.88– 13.40)
9
–
10
–
11
–
12
–
Acarbose[b ]
987.90 (874.70– 1041.20)
a IC50 was afforded with confidence interval (n = 3) and adopted 95% confidence interval; “- ”: IC50 > 100 µmol/L.
b Positive control.